Suzanne van Veen
Overview
Explore the profile of Suzanne van Veen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szachniewicz M, Neustrup M, van den Eeden S, van Meijgaarden K, Franken K, van Veen S, et al.
Int J Pharm
. 2024 Oct;
666:124842.
PMID: 39424087
Tuberculosis (TB) continues to pose a global threat for millennia, currently affecting over 2 billion people and causing 10.6 million new cases and 1.3 million deaths annually. The only existing...
2.
van Meijgaarden K, van Veen S, Tsonaka R, Ruibal P, Roukens A, Arbous S, et al.
Sci Rep
. 2024 Jun;
14(1):12882.
PMID: 38839796
SARS-CoV2 infection results in a range of disease severities, but the underlying differential pathogenesis is still not completely understood. At presentation it remains difficult to estimate and predict severity, in...
3.
Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy
Alonso-Rodriguez N, Vianello E, van Veen S, Jenum S, Tonby K, van Riessen R, et al.
Front Immunol
. 2024 Mar;
15:1350593.
PMID: 38433842
Introduction: Therapeutic vaccination in tuberculosis (TB) represents a Host Directed Therapy strategy which enhances immune responses in order to improve clinical outcomes and shorten TB treatment. Previously, we have shown...
4.
Vianello E, Persson J, Andersson B, van Veen S, Dias T, Santoro F, et al.
iScience
. 2024 Jan;
26(12):108574.
PMID: 38162033
The vectored Ebola vaccine rVSVΔG-ZEBOV-GP elicits protection against Ebola Virus Disease (EVD). In a study of forty-eight healthy adult volunteers who received either the rVSVΔG-ZEBOV-GP vaccine or placebo, we profiled...
5.
Barclay A, Ninaber D, van Veen S, Hiemstra P, Ottenhoff T, van der Does A, et al.
Front Cell Infect Microbiol
. 2023 Oct;
13:1253037.
PMID: 37822359
Lung epithelial cells represent the first line of host defence against foreign inhaled components, including respiratory pathogens. Their responses to these exposures may direct subsequent immune activation to these pathogens....
6.
Impaired resolution of blood transcriptomes through tuberculosis treatment with diabetes comorbidity
Eckold C, van Doorn C, Ruslami R, Ronacher K, Riza A, van Veen S, et al.
Clin Transl Med
. 2023 Aug;
13(9):e1375.
PMID: 37649224
Background: People with diabetes are more likely to develop tuberculosis (TB) and to have poor TB-treatment outcomes than those without. We previously showed that blood transcriptomes in people with TB-diabetes...
7.
Straat M, Martinez-Tellez B, van Eyk H, Bizino M, van Veen S, Vianello E, et al.
J Clin Endocrinol Metab
. 2022 Oct;
108(4):931-940.
PMID: 36262060
Context: South Asian individuals are more prone to develop type 2 diabetes (T2D) coinciding with earlier complications than Europids. While inflammation plays a central role in the development and progression...
8.
Bahrami F, Masoudzadeh N, van Veen S, Persson J, Lari A, Sarvnaz H, et al.
Mol Immunol
. 2022 Jul;
149:165-173.
PMID: 35905592
Cutaneous leishmaniasis (CL) is a neglected tropical disease with severe morbidity and socioeconomic sequelae. A better understanding of underlying immune mechanisms that lead to different clinical outcomes of CL could...
9.
van Doorn C, Eckold C, Ronacher K, Ruslami R, van Veen S, Lee J, et al.
EBioMedicine
. 2022 Jul;
82:104173.
PMID: 35841871
Background: Globally, the tuberculosis (TB) treatment success rate is approximately 85%, with treatment failure, relapse and death occurring in a significant proportion of pulmonary TB patients. Treatment success is lower...
10.
Dos Santos C, Walburg K, van Veen S, Wilson L, Trufen C, Nascimento I, et al.
Vaccines (Basel)
. 2022 Jun;
10(6).
PMID: 35746439
Tuberculosis (TB) is one of the top 10 leading causes of death worldwide. The recombinant BCG strain expressing the genetically detoxified A subunit of the thermolabile toxin from (LTAK63) adjuvant...